Accueil>>Signaling Pathways>> Tyrosine Kinase>> FGFR>>Gunagratinib

Gunagratinib (Synonyms: ICP-192)

Catalog No.GC64875

Le gunagratinib (ICP-192) est un inhibiteur pan-FGFR (récepteurs du facteur de croissance des fibroblastes) À faible toxicité et actif par voie orale qui inhibe puissamment et sélectivement les activités du FGFR de manière irréversible par liaison covalente. Le gunagratinib peut être utilisé pour la recherche sur le cancer.

Products are for research use only. Not for human use. We do not sell to patients.

Gunagratinib Chemical Structure

Cas No.: 2211082-53-8

Taille Prix Stock Qté
5 mg
702,00 $US
En stock
10 mg
1 125,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer[1].

Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding[1].

[1]. Guo Ye, et al. Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations. Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021) 4092-4092.

Avis

Review for Gunagratinib

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Gunagratinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.